Lv D, Lan B, Guo Q, Yi Z, Qian H, Guan Y
BMC Med. 2025; 23(1):122.
PMID: 40001125
PMC: 11863457.
DOI: 10.1186/s12916-025-03959-6.
Wang D, Wang L, Zhang W, Xu K, Chen L, Guo Z
J Nanobiotechnology. 2025; 23(1):129.
PMID: 39979881
PMC: 11843959.
DOI: 10.1186/s12951-025-03205-4.
Marangoni E
Adv Exp Med Biol. 2025; 1464():109-121.
PMID: 39821023
DOI: 10.1007/978-3-031-70875-6_7.
Shea A, Eyal-Lubling Y, Guerrero-Romero D, Manzano Garcia R, Greenwood W, OReilly M
Cancer Res. 2024; 85(3):567-584.
PMID: 39514406
PMC: 7617242.
DOI: 10.1158/0008-5472.CAN-24-1703.
Janitri V, Aruljothi K, Ravi Mythili V, Singh S, Prasher P, Gupta G
MedComm (2020). 2024; 5(10):e745.
PMID: 39329017
PMC: 11424683.
DOI: 10.1002/mco2.745.
Identifying Key Genes Involved in Axillary Lymph Node Metastasis in Breast Cancer Using Advanced RNA-Seq Analysis: A Methodological Approach with GLMQL and MAS.
Rezapour M, Wesolowski R, Gurcan M
Int J Mol Sci. 2024; 25(13).
PMID: 39000413
PMC: 11242629.
DOI: 10.3390/ijms25137306.
Evaluation of Copanlisib in Combination with Eribulin in Triple-negative Breast Cancer Patient-derived Xenograft Models.
Guo Z, Luo J, Mashl R, Hoog J, Maiti P, Fettig N
Cancer Res Commun. 2024; 4(6):1430-1440.
PMID: 38717161
PMC: 11152037.
DOI: 10.1158/2767-9764.CRC-24-0047.
Narazaciclib, a novel multi-kinase inhibitor with potent activity against CSF1R, FLT3 and CDK6, shows strong anti-AML activity in defined preclinical models.
Yang T, Ke H, Liu J, An X, Xue J, Ning J
Sci Rep. 2024; 14(1):9032.
PMID: 38641704
PMC: 11031590.
DOI: 10.1038/s41598-024-59650-y.
Metabolic difference between patient-derived xenograft model of pancreatic ductal adenocarcinoma and corresponding primary tumor.
Wen S, Lin X, Luo W, Pan Y, Liao F, Wang Z
BMC Cancer. 2024; 24(1):485.
PMID: 38632504
PMC: 11022326.
DOI: 10.1186/s12885-024-12193-x.
Progression from ductal carcinoma in situ to invasive breast cancer: molecular features and clinical significance.
Wang J, Li B, Luo M, Huang J, Zhang K, Zheng S
Signal Transduct Target Ther. 2024; 9(1):83.
PMID: 38570490
PMC: 10991592.
DOI: 10.1038/s41392-024-01779-3.
DSBSO-Based XL-MS Analysis of Breast Cancer PDX Tissues to Delineate Protein Interaction Network in Clinical Samples.
Jiao F, Yu C, Wheat A, Chen L, Lih T, Zhang H
J Proteome Res. 2024; 23(8):3269-3279.
PMID: 38334954
PMC: 11296914.
DOI: 10.1021/acs.jproteome.3c00832.
Experimental models for cancer brain metastasis.
Liu Z, Dong S, Liu M, Liu Y, Ye Z, Zeng J
Cancer Pathog Ther. 2024; 2(1):15-23.
PMID: 38328712
PMC: 10846332.
DOI: 10.1016/j.cpt.2023.10.005.
Transferrin receptor in primary and metastatic breast cancer: Evaluation of expression and experimental modulation to improve molecular targeting.
Fontana F, Esser A, Egbulefu C, Karmakar P, Su X, Allen J
PLoS One. 2023; 18(12):e0293700.
PMID: 38117806
PMC: 10732420.
DOI: 10.1371/journal.pone.0293700.
Applications of Innovation Technologies for Personalized Cancer Medicine: Stem Cells and Gene-Editing Tools.
Hasanzadeh A, Ebadati A, Dastanpour L, Aref A, Zangabad P, Kalbasi A
ACS Pharmacol Transl Sci. 2023; 6(12):1758-1779.
PMID: 38093832
PMC: 10714436.
DOI: 10.1021/acsptsci.3c00102.
Patient Derived Xenografts (PDX) Models as an Avatar to Assess Personalized Therapy Options in Uveal Melanoma: A Feasibility Study.
Nemati F, De Koning L, Gentien D, Assayag F, Henry E, Ait Rais K
Curr Oncol. 2023; 30(10):9090-9103.
PMID: 37887557
PMC: 10604955.
DOI: 10.3390/curroncol30100657.
Advances in PET imaging of cancer.
Schwenck J, Sonanini D, Cotton J, Rammensee H, Fougere C, Zender L
Nat Rev Cancer. 2023; 23(7):474-490.
PMID: 37258875
DOI: 10.1038/s41568-023-00576-4.
Cadherins and catenins in cancer: connecting cancer pathways and tumor microenvironment.
Lin W, Cooper L, Anastasiadis P
Front Cell Dev Biol. 2023; 11:1137013.
PMID: 37255594
PMC: 10225604.
DOI: 10.3389/fcell.2023.1137013.
Toward Practical Integration of Omic and Imaging Data in Co-Clinical Trials.
Alkim E, Dowst H, DiCarlo J, Dobrolecki L, Hernandez-Herrera A, Hormuth 2nd D
Tomography. 2023; 9(2):810-828.
PMID: 37104137
PMC: 10144684.
DOI: 10.3390/tomography9020066.
Workflow enabling deepscale immunopeptidome, proteome, ubiquitylome, phosphoproteome, and acetylome analyses of sample-limited tissues.
Abelin J, Bergstrom E, Rivera K, Taylor H, Klaeger S, Xu C
Nat Commun. 2023; 14(1):1851.
PMID: 37012232
PMC: 10070353.
DOI: 10.1038/s41467-023-37547-0.
AKR1C2 Promotes Metastasis and Regulates the Molecular Features of Luminal Androgen Receptor Subtype in Triple Negative Breast Cancer Cells.
Li S, Lee W, Heo W, Son H, Her Y, Kim J
J Breast Cancer. 2023; 26(1):60-76.
PMID: 36762781
PMC: 9981988.
DOI: 10.4048/jbc.2023.26.e1.